Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;34(2):202-9.
doi: 10.1055/s-0034-1381733. Epub 2014 Jun 25.

The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes

Affiliations
Review

The utility of neuroimaging in the differential diagnosis of parkinsonian syndromes

Florian Holtbernd et al. Semin Neurol. 2014 Apr.

Abstract

The differential diagnosis of parkinsonian syndromes can be challenging, particularly in early disease stages. However, prognosis and therapeutic regimes are not alike in Parkinson disease and atypical parkinsonism, and thus a correct diagnosis at the earliest possible stage is desirable. Over the past two decades, magnetic resonance imaging and radiotracer-based imaging techniques have proven to be helpful tools to enhance the accuracy of clinical diagnosis in these disorders. Here, we review recent advances in neuroimaging for the differential diagnosis of parkinsonian syndromes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Structural magnetic resonance imaging in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). (A) T1-weighted image showing hummingbird sign (white arrow) in PSP 1.5 years after onset. (B) Proton density weighted image of pathologically confirmed MSA. Putaminal atrophy with hyperintense putaminal rim (white arrow) on the right and early hyperintense putaminal rim on the left 4.8 years after disease onset. (C) Right middle cerebellar peduncle sign (black arrowhead) and hot cross bun sign (white arrowhead) in pathologically confirmed MSA (T2-weighted image). (Adapted with permission from Massey et al. Conventional Magnetic Resonance Imaging in Confirmed Progressive Supranuclear Palsy and Multiple System Atrophy. Mov Disord 2012; 27:1754–1762.)
Fig. 2
Fig. 2
Disease-related spatial covariance patterns. (A) Parkinson disease-related pattern (PDRP) identified by spatial covariance analysis of 18F-fluorodeoxyglucose positron emission tomography (FDG PET) scans from 33 patients with Parkinson disease and 33 age-matched normal volunteer subjects. This pattern was characterized by relative metabolic increases (red) in the pallidum and thalamus, in the pons and cerebellum, and in the sensorimotor cortex. These changes covaried with metabolic decreases (blue) in the lateral premotor cortex and in parieto-occipital association regions. (Adapted from Ma et al. Abnormal metabolic network activity in Parkinson’s disease: test-rest reproducibility. J Cereb Blood Flow Metab 2007;27:597–605.) (B) Multiple system atrophy-related pattern (MSARP) identified by spatial covariance analysis of FDG PET scans from 10 patients with multiple system atrophy and 10 healthy controls. This pattern was characterized by covarying metabolic decreases (blue) in the putamen and the cerebellum. (Adapted with permission from Eckert et al. Abnormal Metabolic Networks in Atypical Parkinsonism. Mov Disord 2008;23:727–733.) (C) Progressive supranuclear palsy-related pattern (PSPRP) identified by spatial covariance analysis of FDG PET scans from 10 patients with progressive supranuclear palsy and 10 healthy controls. This pattern was characterized by covarying metabolic decreases (blue) in the medial prefrontal cortex, the frontal eye fields, the ventrolateral prefrontal cortex, the caudate nuclei, the medial thalamus, and the upper brainstem. (Adapted with permission from Eckert et al. Abnormal Metabolic Networks in Atypical Parkinsonism. Mov Disord 2008;23:727–733.) (The covariance maps were overlaid on T1-weighted magnetic resonance-template images. Voxels with positive region weights [metabolic increases] are color-coded red and those with negative region weights [metabolic decreases] are color-coded blue.)

Similar articles

Cited by

References

    1. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992;55(3):181–184. - PMC - PubMed
    1. Litvan I, Booth V, Wenning GK, et al. Retrospective application of a set of clinical diagnostic criteria for the diagnosis of multiple system atrophy. J Neural Transm. 1998;105(2-3):217–227. - PubMed
    1. Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord. 2013;28(4):504–509. - PubMed
    1. Postuma RB, Aarsland D, Barone P, et al. Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord. 2012;27(5):617–626. - PubMed
    1. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson’s disease: a systematic review. Mov Disord. 2010;25(2):149–156. - PubMed

Publication types

MeSH terms